Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul:221:44-57.
doi: 10.1016/j.trsl.2020.03.001. Epub 2020 Mar 10.

Emerging molecular mediators and _targets for age-related skeletal muscle atrophy

Lemuel A Brown  1 , Steve D Guzman  1 , Susan V Brooks  2
Affiliations
Review

Emerging molecular mediators and _targets for age-related skeletal muscle atrophy

Lemuel A Brown et al. Transl Res. 2020 Jul.

Abstract

The age-associated decline in muscle mass has become synonymous with physical frailty among the elderly due to its major contribution in reduced muscle function. Alterations in protein and redox homeostasis along with chronic inflammation, denervation, and hormonal dysregulation are all hallmarks of muscle wasting and lead to clinical sarcopenia in older adults. Reduction in skeletal muscle mass has been observed and reported in the scientific literature for nearly 2 centuries; however, identification and careful examination of molecular mediators of age-related muscle atrophy have only been possible for roughly 3 decades. Here we review molecular _targets of recent interest in age-related muscle atrophy and briefly discuss emerging small molecule therapeutic treatments for muscle wasting in sarcopenic susceptible populations.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow chart of sarcopenia clinical trial studies since October 2019. Data received from clinicaltrials.gov. Roughly three quarters of clinical trials have an interventional approach to investigate treatments for sarcopenia. The interventional approaches to retain lean body mass in older adults have been focused more on lifestyle changes (dietary, exercise) and less on patented technologies (drugs, devices).
Figure 2.
Figure 2.
Timeline of interventional clinical trial sarcopenia studies. Sarcopenia studies have gradually increased within the first decade of interventional trials and have abruptly grown within the last decade. Although, production of interventional studies from both the industry and institutions have progressively increased in the past couple decades, drug interventions have remained stable even after the classification of sarcopenia as a disease state in 2016.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ritch A History of geriatric medicine: from Hippocrates to Marjory Warren. J R Coll Physicians Edinb. 2012;42:368–74. - PubMed
    1. Kirkwood TB, Ritter MA. The interface between ageing and health in man. Age Ageing. 1997;26 Suppl 4:9–14. - PubMed
    1. Morley JE, Anker SD, von Haehling S. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014. J Cachexia Sarcopenia Muscle. 2014;5:253–9. - PMC - PubMed
    1. Cesari M, Leeuwenburgh C, Lauretani F, et al. Frailty syndrome and skeletal muscle: results from the Invecchiare in Chianti study. Am J Clin Nutr. 2006;83:1142–8. - PMC - PubMed
    1. Visser M Epidemiology of muscle mass loss with age. Sarcopenia edn. 2012.

Publication types

  NODES
twitter 2